T2 Biosystems, Inc.
TTOO Healthcare Diagnostics & Research
T2 Biosystems, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $7.2 million, down 67.8% from fiscal 2022. Operating cash flow growth for three consecutive years.
Follow TTOO
T2 Biosystems, Inc. (TTOO) EV/Sales
As of 16 October 2026, T2 Biosystems, Inc. (TTOO) trades at a EV/Sales of 6.3×. Over the past ten years it has ranged from −85.5× (May 2015) to 17.8× (July 2024); the current reading is higher than 83% of that period. That is above the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 6.7× | 216.99% |
| FY2022 | 2.1× | 247.45% |
| FY2021 | 0.6× | 83.33% |
| FY2020 | 0.3× | — |
| FY2019 | −1.0× | — |
| FY2018 | −4.6× | — |
| FY2017 | −8.0× | — |
| FY2016 | −7.5× | — |
| FY2015 | −14.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2024 | 10.8× | (36.15%) |
| Jun 2024 | 17.0× | 106.32% |
| Mar 2024 | 8.2× | 22.01% |
| Dec 2023 | 6.7× | (42.77%) |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMTKQ DermTech, Inc. compare | −2.5× |
| ISPC iSpecimen Inc. compare | −1.1× |
| BIAF bioAffinity Technologies, Inc. compare | −0.1× |
| XWEL XWELL, Inc. compare | 0.0× |
| ADVB Advanced Biomed Inc. compare | n/m |
| PMD Psychemedics Corporation compare | 0.7× |
| NOTVQ Inotiv, Inc. compare | 1.6× |
| NDRA ENDRA Life Sciences Inc. compare | 2.2× |
| TTOO T2 Biosystems, Inc. | 6.3× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)